(NASDAQ: KZR) Kezar Life Sciences's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 82.88%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.63%.
Kezar Life Sciences's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast KZR's revenue for 2029 to be $146,242,427, with the lowest KZR revenue forecast at $146,242,427, and the highest KZR revenue forecast at $146,242,427. On average, 1 Wall Street analysts forecast KZR's revenue for 2030 to be $660,324,468, with the lowest KZR revenue forecast at $660,324,468, and the highest KZR revenue forecast at $660,324,468.
In 2031, KZR is forecast to generate $1,323,358,485 in revenue, with the lowest revenue forecast at $1,323,358,485 and the highest revenue forecast at $1,323,358,485.